Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTX Avalo Therapeutics	$8.90 -1.8%	$6.16	$3.39 ▼ $16.00	$117.04M	0.8	114,792 shs	117,904 shs
GNLX Genelux	$3.43 -3.1%	$3.20	$1.95 ▼ $5.89	$129.55M	-0.32	181,603 shs	48,797 shs
IGC IGC Pharma	$0.37 +14.1%	$0.34	$0.25 ▼ $0.48	$33.59M	1.48	913,992 shs	214,616 shs
SCLX Scilex	$17.96 -7.3%	$9.61	$3.60 ▼ $46.20	$125.00M	1.32	125,693 shs	251,796 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTX Avalo Therapeutics	+0.44%	+0.55%	+44.96%	+120.98%	-0.11%
GNLX Genelux	-0.56%	+7.93%	+6.31%	+28.73%	+75.25%
IGC IGC Pharma	+3.53%	+7.32%	+6.72%	+18.32%	-10.98%
SCLX Scilex	+7.19%	+22.50%	+118.74%	+287.60%	-54.98%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVTX Avalo Therapeutics	3.5871 of 5 stars	3.5	5.0	2.6	1.7	1.3
GNLX Genelux	1.5302 of 5 stars	3.6	2.0	1.7	0.0	0.0
IGC IGC Pharma	1.7438 of 5 stars	3.5	0.0	1.7	1.7	0.0
SCLX Scilex	2.1906 of 5 stars	3.3	2.0	2.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTX Avalo Therapeutics	3.00	Buy	$30.00	237.08% Upside
GNLX Genelux	3.20	Buy	$17.75	417.49% Upside
IGC IGC Pharma	3.00	Buy	$3.88	941.67% Upside
SCLX Scilex	2.50	Moderate Buy	$455.00	2,433.41% Upside

Current Analyst Ratings Breakdown

Latest IGC, AVTX, SCLX, and GNLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	AVTX Avalo Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
7/23/2025	GNLX Genelux	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/2/2025	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$15.00

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTX Avalo Therapeutics	$440K	265.99	N/A	N/A	$12.80 per share	0.70
GNLX Genelux	$10K	12,955.11	N/A	N/A	$0.76 per share	4.51
IGC IGC Pharma	$1.27M	26.58	N/A	N/A	$0.08 per share	4.65
SCLX Scilex	$56.59M	2.21	N/A	N/A	($27.68) per share	-0.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTX Avalo Therapeutics	-$35.13M	N/A	0.00	N/A	N/A	N/A	-48.48%	-35.94%	11/6/2025 (Estimated)
GNLX Genelux	-$29.87M	-$0.86	N/A	N/A	N/A	N/A	-107.47%	-83.14%	N/A
IGC IGC Pharma	-$13M	-$0.07	N/A	N/A	N/A	-714.16%	-122.44%	-88.40%	N/A
SCLX Scilex	-$72.81M	-$29.02	N/A	N/A	N/A	-179.12%	N/A	-109.95%	N/A

Latest IGC, AVTX, SCLX, and GNLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	SCLX Scilex	-$4.55	-$7.42	-$2.87	-$7.42	$26.25 million	$9.90 million
8/7/2025	Q2 2025	AVTX Avalo Therapeutics	-$1.43	-$1.92	-$0.49	-$1.92	N/A	N/A
8/7/2025	Q2 2025	GNLX Genelux	-$0.22	-$0.20	+$0.02	-$0.20	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
GNLX Genelux	N/A	N/A	N/A	N/A	N/A
IGC IGC Pharma	N/A	N/A	N/A	N/A	N/A
SCLX Scilex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTX Avalo Therapeutics	N/A	12.44	12.44
GNLX Genelux	N/A	4.18	4.18
IGC IGC Pharma	0.02	1.15	0.98
SCLX Scilex	N/A	0.11	0.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTX Avalo Therapeutics	87.06%
GNLX Genelux	37.33%
IGC IGC Pharma	3.87%
SCLX Scilex	69.67%

Insider Ownership

Company	Insider Ownership
AVTX Avalo Therapeutics	0.25%
GNLX Genelux	8.80%
IGC IGC Pharma	31.48%
SCLX Scilex	7.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTX Avalo Therapeutics	40	13.15 million	13.12 million	Not Optionable
GNLX Genelux	10	37.77 million	34.45 million	Not Optionable
IGC IGC Pharma	61	90.81 million	54.60 million	N/A
SCLX Scilex	80	6.96 million	6.40 million	Optionable

IGC, AVTX, SCLX, and GNLX Headlines

Recent News About These Companies

Scilex (NASDAQ:SCLX) Releases Earnings Results, Misses Estimates By $2.87 EPS

August 15, 2025 | marketbeat.com

Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral ...

August 15, 2025 | theglobeandmail.com

Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex

August 13, 2025 | globenewswire.com

Scilex (SCLX) to Release Quarterly Earnings on Tuesday

August 11, 2025 | americanbankingnews.com

Scilex (SCLX) Expected to Announce Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Scilex (NASDAQ:SCLX) Stock Price Up 3.7% - Time to Buy?

August 2, 2025 | marketbeat.com

Scilex Holding Co. (SCLX) Stock Price Today - WSJ

July 24, 2025 | wsj.com

SCLX Scilex Holding Company - Seeking Alpha

July 1, 2025 | seekingalpha.com

Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in ...

June 25, 2025 | theglobeandmail.com

Scilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board

June 23, 2025 | globenewswire.com

Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal

June 5, 2025 | globenewswire.com

Scilex Holding Stock Price History

June 1, 2025 | investing.com

Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL

May 16, 2025 | globenewswire.com

Scilex adjusts director compensation post-stock split

May 13, 2025 | investing.com

Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.

May 1, 2025 | globenewswire.com

Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule

April 30, 2025 | globenewswire.com

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

April 22, 2025 | globenewswire.com

Scilex Gets Orphan Drug Designation for Its Version of Colchicine

April 17, 2025 | marketwatch.com

Scilex treatment of pericarditis granted FDA orphan designation

April 17, 2025 | markets.businessinsider.com

Scilex confirms FDA awards orphan drug designation for colchicine

April 17, 2025 | markets.businessinsider.com

Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis

April 16, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IGC, AVTX, SCLX, and GNLX Company Descriptions

Avalo Therapeutics NASDAQ:AVTX

$8.90 -0.16 (-1.77%)

Closing price 04:00 PM Eastern

Extended Trading

$8.96 +0.06 (+0.67%)

As of 05:00 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Genelux NASDAQ:GNLX

$3.43 -0.11 (-3.11%)

Closing price 04:00 PM Eastern

Extended Trading

$3.44 +0.00 (+0.15%)

As of 04:04 PM Eastern

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

IGC Pharma NYSEMKT:IGC

$0.37 +0.05 (+14.08%)

Closing price 03:59 PM Eastern

Extended Trading

$0.37 0.00 (-1.08%)

As of 05:32 PM Eastern

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

Scilex NASDAQ:SCLX

$17.96 -1.42 (-7.33%)

Closing price 04:00 PM Eastern

Extended Trading

$18.48 +0.52 (+2.87%)

As of 05:21 PM Eastern

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time